source
- Fresenius Kabi recalls Tyenne (tocilizumab-aazg) 400 mg injection vials over glass particle contaminationFresenius Kabi announced a recall of a specific lot of its Tyenne (tocilizumab-aazg) injection, 400 mg/20 mL vials, after detecting glass particles in the product. The company said the contaminati…
- Regeneron Ventures leads $75 million Series A for eczema-focused antibody startup InfinimmuneInfinimmune, a Bay Area biotech developing antibody therapies for eczema, announced a $75 million Series A financing round. The round was co-led by Regeneron Ventures and Playground Global, with p…Fierce Biotech · 1d agoDealPositive